Glycate ® (Glycopyrrolate Tablets, USP) 1.5 mg

Manufacturer
Carwin Pharmaceutical Associates, LLC
Effective date
2020-12-28
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
legacy-cache
Hydrated at
2026-08-01 22:59:44

Label at a glance#

ProductGLYCATE
Active ingredientGLYCOPYRROLATE
Label structure12 sections

Indications and uses

For use as adjunctive therapy in the treatment of peptic ulcer.

Dosage and administration

The dosage of Glycopyrrolate Tablets, USP should be adjusted to the needs of the individual patient to assure symptomatic controlwith a minimum of adverse reactions. The presently recommended maximum daily dosage of glycopyrrolate is 8 mg. The recommended initial dosage of Glycopyrrolate 1 mg tablets for adults is one tablet three times daily (in the morning, early afternoon, and at bedtime). Some patients may req...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Glycopyrrolate Tablets, USP 1.5 mg contains the synthetic anticholinergic, glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentylhydroxyacetyl) oxy]-1,1-dimethylpyrrolidinium bromide.

                                                  C19H28BrNO3 MW: 398.33                                                  C19H28BrNO3 MW: 398.33

Each tablet contains:

Glycopyrrolate, USP1.5 mg

Inactive Ingredients: Dibasic Calcium Phosphate, Anhydrous Lactose, Magnesium Stearate, Povidone, Sodium Starch Glycolate

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine by lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sino-atrial node, the atrioventricular node, exocrine glands, and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.

Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases.

The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are non-polar tertiary amines which penetrate lipid barriers easily.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For use as adjunctive therapy in the treatment of peptic ulcer.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

WARNINGS

WARNINGS SECTION

In the presence of a high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with the use of Glycopyrrolate Tablets, USP.

Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.

Glycopyrrolate Tablets, USP may produce drowsiness or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking this drug.

Theoretically, with overdosage, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis.

PRECAUTIONS

PRECAUTIONS SECTION

Use Glycopyrrolate Tablets, USP with caution in the elderly and in all patients with:

  • Autonomic neuropathy.
  • Hepatic or renal disease.
  • Ulcerative colitis - large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason may precipitate or aggravate the "toxic megacolon," a serious complication of the disease.
  • Hyperthyroidism, coronary heart disease, congestive heart failure, cardiac tachyarrhythmias, tachycardia, hypertension and prostatic hypertrophy.
  • Hiatal hernia associated with reflux esophagitis, since anticholinergic drugs may aggravate this condition.

Interactions

DRUG INTERACTIONS SECTION

There are no known drug interactions.

Pregnancy

PREGNANCY SECTION

The safety of this drug during pregnancy has not been established. The use of any drug during pregnancy requires that the potential benefits of the drug be weighed against possible hazards to mother and child. Reproduction studies in rats revealed no teratogenic effects from glycopyrrolate; however, the potent anticholinergic action of this agent resulted in diminished rates of conception and of survival at weaning, in a dose-related manner. Other studies in dogs suggest that this may be due to diminished seminal secretion which is evident at high doses of glycopyrrolate. Information on possible adverse effects in the pregnant female is limited to uncontrolled data derived from marketing experience. Such experience has revealed no reports of teratogenic or other fetus-damaging potential. No controlled studies to establish the safety of the drug in pregnancy have been performed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

Pediatric Use

PEDIATRIC USE SECTION

Since there is no adequate experience in pediatric patients who have received this drug, safety and efficacy in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Anticholinergics produce certain effects, most of which are extensions of their fundamental pharmacological actions. Adverse reactions to anticholinergics in general may include xerostomia; decreased sweating; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; dilation of the pupil; cycloplegia; increased ocular tension; loss of taste; headaches; nervousness; mental confusion; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; constipation; bloated feeling; impotence; suppression of lactation; severe allergic reaction or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.

Glycopyrrolate Tablets, USP is chemically a quaternary ammonium compound; hence, its passage across lipid membranes, such as the blood-brain barrier, is limited in contrast to atropine sulfate and scopolamine hydrobromide. For this reason the occurrence of CNS related side effects is lower, in comparison to their incidence following administration of anticholinergics which are chemically tertiary amines that can cross this barrier readily.

Call your doctor for medical advice about side effects. You may voluntarily report side effects to FDA AT 1-800-FDA-1088. Questions or comments? Call Carwin Pharmaceutical Associates, LLC at 1-844-700-5011.

OVERDOSAGE

OVERDOSAGE SECTION

The symptoms of overdosage of glycopyrrolate are peripheral in nature rather than central.

  1. To guard against further absorption of the drug - use gastric lavage, cathartics, and/or enemas.
  2. To combat peripheral anticholinergic effects (residual mydriasis, dry mouth, etc.) - utilize a quaternary ammonium anticholinesterase, such as neostigmine methylsulfate.
  3. To combat hypotension - use pressor amines (norepinephrine, metaraminol) i.v.; and supportive care.
  4. To combat respiratory depression - administer oxygen; utilize a respiratory stimulant such as Dopram® i.v.; artificial respiration.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dosage of Glycopyrrolate Tablets, USP should be adjusted to the needs of the individual patient to assure symptomatic controlwith a minimum of adverse reactions. The presently recommended maximum daily dosage of glycopyrrolate is 8 mg.

Glycopyrrolate Tablets, USP 1 mg

SPL UNCLASSIFIED SECTION

The recommended initial dosage of Glycopyrrolate 1 mg tablets for adults is one tablet three times daily (in the morning, early afternoon, and at bedtime). Some patients may require two tablets at bedtime to assure overnight control of symptoms.

For maintenance, a dosage of one tablet twice a day is frequently adequate.

Glycopyrrolate Tablets, USP 2 mg

SPL UNCLASSIFIED SECTION

The recommended dosage of Glycopyrrolate 2 mg tablets for adults is one tablet two or three times daily at equally spaced intervals.

Glycopyrrolate Tablets, USP 1.5 mg

SPL UNCLASSIFIED SECTION

The Glycopyrrolate 1.5 mg tablets may be used to provide intermediate titration doses based on response of the patient.

Glycopyrrolate Tablets, USP are not recommended for use in pediatric patients under the age of 12 years.

HOW SUPPLIED

HOW SUPPLIED SECTION

Glycate® (Glycopyrrolate Tablets, USP) 1.5 mg are compressed white tablets debossed GP on one side and 1.5 on the other and are supplied in bottles of 100 (15370-160-10) and a physician sample (15370-160-03).

STORAGE AND HANDLING SECTION

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

Keep out of reach of children.

Dispense in tight container.

SPL UNCLASSIFIED SECTION

Rx Only

Manufactured for:
Carwin Pharmaceutical Associates, LLC
Hazlet, NJ 07730
www.carwinpharma.com

Rev. 05/18

PRINCIPAL DISPLAY PANEL - 1.5 mg Tablet Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 15370-160-10

Glycate®
(Glycopyrrolate
Tablets, USP 1.5 mg)

WHITE DYE-FREE

100 Tablets
Rx Only

carwin
PHARMACEUTICAL ASSOCIATES

PRINCIPAL DISPLAY PANEL - 1.5 mg Tablet Bottle Label
PRINCIPAL DISPLAY PANEL - 1.5 mg Tablet Bottle Label

FDA-Initiated Inactive NDC Indexing#

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
15370-160-10EA - Each15370-160c109a933-f2da-4cdd-83f5-d63da2254c2312018-07-03

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
15370-16015370-160-10, 15370-160-03

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A091522-001GLYCOPYRROLATEGLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-12

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-1284e616aacf4f…
2026-08-18 06:07:402026-07A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-12caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-12011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-1231067a03dcf5…
2025-08-23 18:47 UTC2025-08A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-126a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-12fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-12b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-1203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-122680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-125bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-12d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-12d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A091522-001GLYCOPYRROLATE1.5MGTABLET / ORALRS2012-03-1279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-121e350fbaab3a…
2024-05-31 18:47 UTC2024-05A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-128072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-125c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-125d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-124b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-1274a2ff9319b5…
2022-03-09 01:35 UTC2022-03A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-1287673890dc5c…
2021-03-12 10:30 UTC2021-03A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-125aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-128869cabd3fbd…
2020-11-12 02:37 UTC2020-11A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12c0c555d07b60…
2019-12-14 00:12 UTC2019-12A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-123f01610625f2…
2019-09-15 20:21 UTC2019-09A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12b00525d2431f…
2019-07-19 19:46 UTC2019-07A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-126a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-121c564ffb4f44…
2023-12-20 04:57 UTC2023-12A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-129b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-123f0d92c62455…
2023-05-13 08:27 UTC2023-05A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12053a50430f4f…
2023-01-26 05:58 UTC2023-01A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-123bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-123a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A091522-001GLYCOPYRROLATE1.5MGTABLET / ORAL2012-03-12f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
a89ae893-b9dc-4dc1-9fea-87da827225ac8f5dfdb4-67cc-42b5-85fd-0d4e50f66fe82023-01-19Warnings, Adverse reactionsExact identifier
spl set id: 8f5dfdb4-67cc-42b5-85fd-0d4e50f66fe8

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.